IFNL4 Genotype for Predicting Response to Ledipasvir/Sofosbuvir: Kaiser Permanente Northern California
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 10 Jul 2019
Price : $35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Pharmacogenomic; Therapeutic Use
- 05 Jul 2019 Planned initiation date changed from 9 Jul 2019 to 15 Jul 2019.
- 05 Jul 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Jul 2019 Planned initiation date changed from 5 Jul 2019 to 9 Jul 2019.